WT1-coTCR

WT1-coTCR (conventional Wilms tumor 1-specific T-cell receptor) is an experimental adoptive T-cell therapy designed for the treatment of malignancies, particularly leukemia. It involves the genetic engineering of T cells using a conventional MS-bPa retroviral vector to express a T-cell receptor (TCR) specific to the WT1 antigen, restricted by HLA-A*24:02. The TCR genes (Vα20/J33/Cα and Vβ5.1/J2.1/Cβ2) were originally cloned from the TAK-1 cytotoxic T-lymphocyte (CTL) clone. Unlike the improved "siTCR" version, WT1-coTCR does not incorporate siRNA to silence endogenous TCR chains, which can lead to TCR mispairing and reduced surface expression of the therapeutic TCR. It was developed by researchers at Ehime University Graduate School of Medicine to redirect T cells to recognize and lyse WT1-expressing leukemia cells.

Other names

conventional WT1-TCRconventional WT1-TCR gene-transduced T cells